Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients
after neoadjuvant chemoradiotherapy in locally advanced ESCC. And then the patients would
receive surgery and adjuvant therapy according to the postoperative pathological results. It
is expected that through this study, some high-risk patients could obtain better efficacy and
prolong patient survival. At same time, low risk patients could avoid increasing
perioperative complications and surgical risks, so that more patients could benefit from
neoadjuvant treatment. The investigators aimed to explore a more accurate comprehensive
treatment mode for patients with esophageal squamous cell carcinoma, and provide a certain
scientific basis for the formulation of esophageal cancer diagnosis and treatment norms in
China.